← All trials
NCT05266924
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2022
- Primary completion
- Aug 31, 2023
- Completion date
- Nov 30, 2023
- First posted
- Mar 4, 2022
- Last posted
- Jul 27, 2022
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bharat Serums and Vaccines LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.